Skip to main content

Table 3 Regression models

From: Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients

  Estimates CI p value
Total vBMD
 Intercept 362.37 325.84–398.90 < 0.001
 Age − 1.57 − 2.23 to − 0.91 < 0.001
 Female 9.09 − 13.47–31.65 0.427
 bDMARDs 43.52 18.18–68.86 0.001
 Methotrexate 12.12 − 17.47–41.71 0.420
Stiffness
 Intercept 68.65 60.90–76.40 < 0.001
 Age − 0.28 − 0.42 to − 0.14 < 0.001
 Female − 15.66 − 20.51 to − 10.82 < 0.001
 bDMARDs 6.81 1.43–12.18 0.013
 Methotrexate − 0.67 − 7.06–5.72 0.835
Failure load
 Intercept 3227.06 2879.26–3574.86 < 0.001
 Age − 12.77 − 19.06 to − 6.49 < 0.001
 Female −  732.60 − 949.97 to − 515.22 < 0.001
 bDMARDs 322.23 80.84–563.63 0.009
 Methotrexate − 4.88 − 291.73–281.97 0.973
  1. Reference for the change is the no treatment group. Models are adjusted for age, gender, and treatment-gender interaction
  2. vBMD volumetric bone mineral density, bDMARDs biologic disease-modifying anti-rheumatic drugs, CI confidence interval